Single-Dose Oral Treatment for Sleeping Sickness Gets Regulatory Backing

A new, single-dose oral treatment for human African trypanosomiasis – commonly known as sleeping sickness – has received a positive regulatory review from the European Medicines Agency (EMA). The approval, announced February 27, 2026, is for apply outside of the European Union and offers a significantly simplified treatment pathway for a disease that historically required invasive procedures and lengthy hospital stays. This development could dramatically improve access to care and treatment adherence for those affected by this neglected tropical disease.

Understanding Human African Trypanosomiasis

Human African trypanosomiasis is a parasitic infection transmitted by the bite of infected tsetse flies. The disease is found in 36 sub-Saharan African countries. The World Health Organization (WHO) details two forms of the disease: Trypanosoma brucei gambiense, which accounts for over 95% of reported cases and causes a chronic infection, and Trypanosoma brucei rhodesiense, which causes a more acute and rapidly progressing illness. Without treatment, sleeping sickness is almost invariably fatal.

Historically, diagnosis has relied on identifying the parasite in blood, lymph node aspirates, or cerebrospinal fluid – the latter requiring a lumbar puncture, often referred to as a spinal tap. Treatment regimens have been complex, involving multiple injections and hospitalisation, posing significant logistical and accessibility challenges, particularly in remote areas.

Acoziborole Winthrop: A Simplified Approach

The newly reviewed treatment, Acoziborole Winthrop, represents a major step forward. According to the EMA’s announcement, the single oral dose is effective against all stages of T. Brucei gambiense sleeping sickness. This eliminates the demand for lumbar puncture to determine disease stage and removes the requirement for hospitalisation. The simplification of treatment is expected to improve patient compliance and overall accessibility to care.

The EMA’s review focused on the drug’s efficacy and safety for use outside the EU, a common pathway for treatments targeting diseases disproportionately affecting low- and middle-income countries. The agency’s backing is a crucial step towards wider availability, though final approval and implementation will depend on national regulatory authorities in affected countries.

The Diagnostic Shift and Treatment Stages

Traditionally, treatment selection for sleeping sickness has been guided by the stage of the disease, determined through lumbar puncture. The first stage involves the parasite circulating in the blood and lymph, while the second stage sees the parasite cross the blood-brain barrier and infect the central nervous system. Acoziborole Winthrop’s effectiveness across all stages is a significant advantage, streamlining the treatment process and reducing the burden on healthcare systems.

The EMA’s assessment suggests that Acoziborole Winthrop’s single-dose oral administration offers a substantial improvement over existing treatments. Medscape News Europe reports that the regulator backed the approach specifically to spare patients the need for lumbar puncture and inpatient care. This is particularly important in regions with limited healthcare infrastructure and resources.

What This Means for Patients and Public Health

The availability of a single-dose oral treatment has the potential to transform the management of sleeping sickness. Reduced treatment complexity translates to fewer disruptions to patients’ lives, lower healthcare costs, and increased treatment rates. Improved accessibility is particularly critical for populations in remote areas where access to healthcare facilities is limited.

However, it’s important to note that the EMA’s review is specifically for use outside the EU. The drug’s availability and implementation will vary depending on individual country approvals and healthcare policies. Continued surveillance and monitoring will be essential to assess the long-term efficacy and safety of Acoziborole Winthrop in real-world settings.

Monitoring and Future Steps

The EMA’s positive review is not the final step. National regulatory authorities in affected countries will now need to assess the data and determine whether to approve Acoziborole Winthrop for use within their borders. The WHO will likely play a key role in providing guidance and support to countries in implementing the new treatment.

Post-market surveillance will be crucial to monitor the drug’s effectiveness, identify any potential adverse effects, and track the emergence of drug resistance. Ongoing research will also be needed to explore the potential for combining Acoziborole Winthrop with other interventions to further improve the control and elimination of sleeping sickness. The simplification of treatment represents a significant advance, but sustained commitment to research, surveillance, and access is essential to achieve lasting progress against this debilitating disease.